Skip to main content
SpringerLink
Log in
Book cover

Endocrine Disorders in Kidney Disease pp 277–290Cite as

Adiponectin and Leptin in Kidney Disease Patients

  • Chapter
  • First Online:

Abstract

Adiponectin is a type of adipokine, namely, a hormonally active molecule secreted by adipose tissue with pervasive effects on multiple organ systems. In the general population, adiponectin has demonstrated anti-inflammatory and cardioprotective properties, and a number of studies have shown that higher levels are associated with favorable cardiovascular outcomes and survival. However, in patients with non-dialysis-dependent (NDD) and dialysis-dependent chronic kidney disease (CKD), higher adiponectin levels have been paradoxically associated with adverse cardiovascular outcomes and higher mortality risk. Similarly, leptin is an adipokine which has been identified as having an important role in the regulation of inflammation and energy metabolism. In the general population, high serum leptin has been associated with adverse cardiovascular outcomes, but these observations are in contradistinction to findings observed in patients with end-stage renal disease (ESRD). The objective of this chapter is to review and discuss the existing body of evidence examining the interrelationships of adiponectin and leptin and outcomes in the general population as well as in those with varying degrees of impaired kidney function.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Matsuda M, Tamura R, Kishida N, et al. Predictive value of adiponectin in patients with multivessel coronary atherosclerosis detected on computed tomography angiography. J Atheroscler Thromb. 2013;20:767–76.

    Article  CAS  Google Scholar 

  2. Kawagoe J, Ishikawa T, Iwakiri H, Date H, Imamura T, Kitamura K. Association between adiponectin production in coronary circulation and future cardiovascular events in patients with coronary artery disease. Int Heart J. 2014;55:239–43.

    Article  CAS  Google Scholar 

  3. Yoon JH, Kim SK, Choi HJ, et al. Adiponectin provides additional information to conventional cardiovascular risk factors for assessing the risk of atherosclerosis in both genders. PLoS One. 2013;8:e75535.

    Article  CAS  Google Scholar 

  4. Yamashita T, Matsuda M, Nishimoto O, et al. Combination of serum adiponectin level and metabolic syndrome is closely associated with coronary artery disease in Japanese subjects with good glycemic control. Intern Med. 2010;49:721–7.

    Article  CAS  Google Scholar 

  5. Komura N, Kihara S, Sonoda M, et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J. 2008;72:23–8.

    Article  CAS  Google Scholar 

  6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.

    Article  CAS  Google Scholar 

  7. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98:1603–8.

    Article  CAS  Google Scholar 

  8. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–606.

    Article  CAS  Google Scholar 

  9. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int. 2008;74:649–54.

    Article  CAS  Google Scholar 

  10. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:134–41.

    Article  CAS  Google Scholar 

  11. Diez JJ, Estrada P, Bajo MA, et al. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol. 2009;30:244–52.

    Article  CAS  Google Scholar 

  12. Takemoto F, Katori H, Sawa N, et al. Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients--a Japanese prospective eight-year study. Nephron Clin Pract. 2009;111:c12–20.

    Article  CAS  Google Scholar 

  13. Abdallah E, Waked E, Nabil M, El-Bendary O. Adiponectin and cardiovascular outcomes among hemodialysis patients. Kidney Blood Press Res. 2012;35:247–53.

    Article  CAS  Google Scholar 

  14. Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int. 2009;76:567–75.

    Article  CAS  Google Scholar 

  15. Rao M, Li L, Tighiouart H, et al. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant. 2008;23:2619–28.

    Article  CAS  Google Scholar 

  16. Alam A, Molnar MZ, Czira ME, et al. Serum adiponectin levels and mortality after kidney transplantation. Clin J Am Soc Nephrol. 2013;8:460–7.

    Article  CAS  Google Scholar 

  17. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). 1996. Biochem Biophys Res Commun. 2012;425:556–9.

    Article  CAS  Google Scholar 

  18. Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913.

    Article  Google Scholar 

  19. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62.

    Article  CAS  Google Scholar 

  20. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137–45.

    Article  CAS  Google Scholar 

  21. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28:15–23.

    Article  CAS  Google Scholar 

  22. Cammisotto PG, Bendayan M. Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol. 2008;39:579–84.

    Article  CAS  Google Scholar 

  23. Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:1910–7.

    Article  CAS  Google Scholar 

  24. Jeon WS, Park JW, Lee N, et al. Urinary adiponectin concentration is positively associated with micro- and macro-vascular complications. Cardiovasc Diabetol. 2013;12:137.

    Article  Google Scholar 

  25. Jorsal A, Petersen EH, Tarnow L, et al. Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. J Diabetes Complicat. 2013;27:604–8.

    Article  Google Scholar 

  26. Kopf S, Oikonomou D, von Eynatten M, et al. Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol. 2014;51:479–89.

    CAS  PubMed  Google Scholar 

  27. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.

    Article  CAS  Google Scholar 

  28. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.

    Article  CAS  Google Scholar 

  29. Statnick MA, Beavers LS, Conner LJ, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000;1:81–8.

    Article  CAS  Google Scholar 

  30. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.

    Article  CAS  Google Scholar 

  31. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.

    Article  CAS  Google Scholar 

  32. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.

    Article  CAS  Google Scholar 

  33. Pereira RI, Snell-Bergeon JK, Erickson C, et al. Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clin Endocrinol Metab. 2012;97:E642–7.

    Article  CAS  Google Scholar 

  34. Hadjadj S, Aubert R, Fumeron F, et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia. 2005;48:1088–92.

    Article  CAS  Google Scholar 

  35. Saraheimo M, Forsblom C, Thorn L, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care. 2008;31:1165–9.

    Article  CAS  Google Scholar 

  36. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47–50.

    Article  CAS  Google Scholar 

  37. Lee FP, Jen CY, Chang CC, et al. Mechanisms of adiponectin-mediated COX-2 induction and protection against iron injury in mouse hepatocytes. J Cell Physiol. 2010;224:837–47.

    Article  CAS  Google Scholar 

  38. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–6.

    Article  CAS  Google Scholar 

  39. Cheng KK, Lam KS, Wang Y, et al. Erratum. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes. 2007;56:1387–94. Diabetes 2016;65:3218.

    Article  Google Scholar 

  40. Wu Z, Cheng Y, Aung LH, Li B. Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis. PLoS One. 2013;8:e78485.

    Article  CAS  Google Scholar 

  41. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091–8.

    Article  CAS  Google Scholar 

  42. Zoccali C, Postorino M, Marino C, et al. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med. 2011;269:172–81.

    Article  CAS  Google Scholar 

  43. Chudek J, Adamczak M, Karkoszka H, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003;35:2186–9.

    Article  CAS  Google Scholar 

  44. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A. Plasma adiponectin concentration in patients after successful kidney transplantation – a single-center, observational study. Clin Nephrol. 2007;67:381–90.

    Article  CAS  Google Scholar 

  45. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130:671–80.

    Article  CAS  Google Scholar 

  46. Hukshorn CJ, Lindeman JH, Toet KH, et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab. 2004;89:1773–8.

    Article  CAS  Google Scholar 

  47. Dervisoglu E, Eraldemir C, Kalender B, Kir HM, Caglayan C. Adipocytokines leptin and adiponectin, and measures of malnutrition-inflammation in chronic renal failure: is there a relationship? J Ren Nutr. 2008;18:332–7.

    Article  Google Scholar 

  48. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9. quiz 20

    Article  CAS  Google Scholar 

  49. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol. 1997;8:1423–30.

    CAS  PubMed  Google Scholar 

  50. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol. 1998;9:1080–4.

    CAS  PubMed  Google Scholar 

  51. Nishizawa Y, Shoji T, Tanaka S, et al. Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis. 1998;31:655–61.

    Article  CAS  Google Scholar 

  52. Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care. 2009;32:612–6.

    Article  CAS  Google Scholar 

  53. Vavruch C, Lanne T, Fredrikson M, Lindstrom T, Ostgren CJ, Nystrom FH. Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:62.

    Article  Google Scholar 

  54. Batsis JA, Sahakyan KR, Singh P, Bartels SJ, Somers VK, Lopez-Jimenez F. Leptin, adiposity, and mortality: results from the National Health and nutrition examination survey III, 1988 to 1994. Mayo Clin Proc. 2015;90:481–91.

    Article  CAS  Google Scholar 

  55. Adya R, Tan BK, Randeva HS. Differential effects of leptin and adiponectin in endothelial angiogenesis. J Diabetes Res. 2015;2015:648239.

    Article  Google Scholar 

  56. Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab. 1997;82:847–50.

    CAS  PubMed  Google Scholar 

  57. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol. 2005;62:242–9.

    Article  CAS  Google Scholar 

  58. Diez JJ, Bossola M, Fernandez-Reyes MJ, et al. Relationship between leptin and all-cause and cardiovascular mortality in chronic hemodialysis patients. Nefrologia. 2011;31:206–12.

    PubMed  Google Scholar 

  59. Bian X, Liu N, Bai Y, et al. Association of leptin with mortality in patients on maintenance hemodialysis: a prospective study. Iran J Kidney Dis. 2014;8:314–20.

    PubMed  Google Scholar 

  60. Nasri H. Association of serum leptin with anemia in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl. 2006;17:521–5.

    PubMed  Google Scholar 

  61. Park JT, Yoo TH, Kim JK, et al. Leptin/adiponectin ratio is an independent predictor of mortality in nondiabetic peritoneal dialysis patients. Perit Dial Int. 2013;33:67–74.

    Article  CAS  Google Scholar 

  62. Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol. 2006;58:189–93.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology Associates Medical Group, Riverside, CA, USA

    Jerry Zhong Yu

  2. Division of Nephrology and Hypertension, Departments of Medicine, Pediatrics, Public Health, and Nursing Sciences, University of California Irvine School of Medicine, Orange, CA, USA

    Kamyar Kalantar-Zadeh

  3. Division of Nephrology and Hypertension, Departments of Medicine and Public Health, University of California Irvine School of Medicine, Orange, CA, USA

    Connie M. Rhee

Authors
  1. Jerry Zhong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamyar Kalantar-Zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Connie M. Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nephrology and Hypertension, Departments of Medicine and Public Health, University of California Irvine, School of Medicine, Orange, CA, USA

    Connie M. Rhee

  2. Division of Nephrology and Hypertension, Departments of Medicine, Pediatrics, Public Health, and Nursing Sciences, University of California Irvine, School of Medicine, Orange, CA, USA

    Kamyar Kalantar-Zadeh

  3. Division of Endocrinology, Diabetes, and Hypertension, Departments of Medicine and Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Gregory A. Brent

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yu, J.Z., Kalantar-Zadeh, K., Rhee, C.M. (2019). Adiponectin and Leptin in Kidney Disease Patients. In: Rhee, C., Kalantar-Zadeh, K., Brent, G. (eds) Endocrine Disorders in Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-97765-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97765-2_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97763-8

  • Online ISBN: 978-3-319-97765-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation